Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14233518 | 1.00 | SLC6A3 (0.43) | SLC6A3GSRMEN1KMT2AKDM4C | |
| SCHEMBL5160820 | 1.00 | SLC6A3 (0.43) | SLC6A3GSRMEN1KMT2AKDM4C | |
| SCHEMBL5160815 | 1.00 | SLC6A3 (0.43) | SLC6A3GSRMEN1KMT2AKDM4C | |
| SCHEMBL16070743 | 0.86 | MEN1 (0.34) | SLC6A3MEN1KMT2AKDM4CPTGER4 | |
| SCHEMBL11936252 | 0.85 | SLC6A3 (0.43) | SLC6A3MEN1KMT2AKDM4CHPGD | |
| SCHEMBL7151281 | 0.85 | SLC6A3 (0.40) | SLC6A3MEN1KMT2AKDM4CHPGD | |
| SCHEMBL7260416 | 0.85 | PTGER4 (0.44) | SLC6A3PRKG1PTGER4 | |
| SCHEMBL7260421 | 0.85 | PTGER4 (0.44) | SLC6A3PRKG1PTGER4 | |
| SCHEMBL5156166 | 0.85 | PTGER4 (0.44) | SLC6A3PRKG1PTGER4 | |
| SCHEMBL5156160 | 0.85 | PTGER4 (0.44) | SLC6A3PRKG1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2464632-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-7261836-B2 | Chiral dopant with phenylethanediol functionality | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2007-08-28 | — | — | US | disclosed |
| US-7261836-B2 | Chiral dopant with phenylethanediol functionality | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2007-08-28 | — | — | US | disclosed |
| US-7261836-B2 | Chiral dopant with phenylethanediol functionality | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2007-08-28 | — | — | US | disclosed |
| US-20060022167-A1 | Chiral dopant with phenylethanediol functionality | KONINKLIJKE PHILIPS ELECTRONICS N.V. | 2006-02-02 | — | — | US | disclosed |
| EP-1519910-A1 | CHIRAL DOPANT WITH PHENYLETHANEDIOL FUNCTIONALITY | Koninklijke Philips Electronics N.V. (NL) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004002935-A1 | CHIRAL DOPANT WITH PHENYLETHANEDIOL FUNCTIONALITY | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208797-A1 | PYRIMIDONE DERIVATIVES | PSEN1, PRNP, PSEN2 | SLC6A3 841/4885GSR 1327/4885MEN1 2639/4885 |
| US-20060022167-A1 | Chiral dopant with phenylethanediol functionality | CRY2, CRY1, DDT | SLC6A3 930/4885GSR 3616/4885MEN1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.